We’ve recently updated our valuation analysis.

Achieve Life Sciences Valuation

Is ACHV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACHV?

Other financial metrics that can be useful for relative valuation.

ACHV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does ACHV's PB Ratio compare to its peers?

The above table shows the PB ratio for ACHV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.4x
AIM AIM ImmunoTech
0.5x13.1%US$21.7m
OGEN Oragenics
1.9x-21.0%US$22.3m
SIOX Sio Gene Therapies
0.5x39.5%US$22.0m
SHPH Shuttle Pharmaceuticals Holdings
2.8xn/aUS$23.4m
ACHV Achieve Life Sciences
26.8x47.8%US$28.0m

Price-To-Book vs Peers: ACHV is expensive based on its Price-To-Book Ratio (26.8x) compared to the peer average (1.4x).


Price to Earnings Ratio vs Industry

How does ACHV's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.4%
n/an/an/a

Price-To-Book vs Industry: ACHV is expensive based on its Price-To-Book Ratio (26.8x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is ACHV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACHV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio26.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ACHV's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ACHV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACHV ($2.88) is trading below our estimate of fair value ($453.41)

Significantly Below Fair Value: ACHV is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACHV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.88
US$28.13
+876.6%
62.7%US$71.00US$8.00n/a8
Nov ’23US$2.23
US$31.75
+1,323.8%
49.0%US$71.00US$20.00n/a8
Oct ’23US$3.30
US$31.75
+862.1%
49.0%US$71.00US$20.00n/a8
Sep ’23US$4.45
US$31.75
+613.5%
49.0%US$71.00US$20.00n/a8
Aug ’23US$4.98
US$31.75
+537.6%
49.0%US$71.00US$20.00n/a8
Jul ’23US$4.91
US$31.75
+546.6%
49.0%US$71.00US$20.00n/a8
Jun ’23US$6.76
US$31.75
+369.7%
49.0%US$71.00US$20.00n/a8
May ’23US$6.93
US$34.13
+392.4%
52.2%US$75.00US$20.00n/a8
Apr ’23US$7.55
US$31.50
+317.2%
42.9%US$58.00US$20.00n/a8
Mar ’23US$7.10
US$31.50
+343.7%
42.9%US$58.00US$20.00n/a8
Feb ’23US$7.55
US$31.50
+317.2%
42.9%US$58.00US$20.00n/a8
Jan ’23US$7.78
US$31.50
+304.9%
42.9%US$58.00US$20.00n/a8
Dec ’22US$6.87
US$31.50
+358.5%
42.9%US$58.00US$20.00n/a8
Nov ’22US$8.36
US$35.25
+321.7%
58.1%US$80.00US$20.00US$2.238
Oct ’22US$8.45
US$36.71
+334.5%
58.6%US$80.00US$20.00US$3.307
Sep ’22US$8.19
US$39.50
+382.3%
55.7%US$80.00US$21.00US$4.456
Aug ’22US$7.31
US$42.83
+486.0%
66.5%US$100.00US$21.00US$4.986
Jul ’22US$8.95
US$42.83
+378.6%
66.5%US$100.00US$21.00US$4.916
Jun ’22US$8.21
US$45.20
+450.5%
64.6%US$100.00US$21.00US$6.765
May ’22US$10.79
US$45.20
+318.9%
64.6%US$100.00US$21.00US$6.935
Apr ’22US$11.55
US$45.20
+291.3%
64.6%US$100.00US$21.00US$7.555
Mar ’22US$11.62
US$45.20
+289.0%
64.6%US$100.00US$21.00US$7.105
Feb ’22US$12.09
US$45.20
+273.9%
64.6%US$100.00US$21.00US$7.555
Jan ’22US$8.10
US$45.00
+455.6%
65.1%US$100.00US$21.00US$7.785
Dec ’21US$8.59
US$45.00
+423.9%
65.1%US$100.00US$21.00US$6.875
Nov ’21US$7.86
US$43.00
+447.1%
68.0%US$100.00US$21.00US$8.365

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies